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Cardiovascular disease is the leading cause of death. The disease is due to atherosclerosis which is characterized by lipid and fat
accumulation in arterial blood vessel walls. A key causative event is the accumulation of oxidised low density lipoprotein particles
within vascular cells, and this is mediated by scavenger receptors. One such molecule is the LOX-1 scavenger receptor that is
expressed on endothelial, vascular smooth muscle, and lymphoid cells including macrophages. LOX-1 interaction with OxLDL
particles stimulates atherosclerosis. LOX-1 mediates OxLDL endocytosis via a clathrin-independent internalization pathway.
Transgenic animal model studies show that LOX-1 plays a signiﬁcant role in atherosclerotic plaque initiation and progression.
Administration of LOX-1 antibodies in cellular and animal models suggest that such intervention inhibits atherosclerosis.
Antiatherogenic strategies that target LOX-1 function using gene therapy or small molecule inhibitors would be new ways to
address the increasing incidence of vascular disease in many countries.
1.Background
Cholesterol is a key cellular molecule that is vital to growth
and repair and is also a major component of the mammalian
plasma membrane bilayer. It is also required for the synthesis
of steroid hormones and bile salts. However, an elevated
level of serum cholesterol and in particular, the low-density
lipoprotein (LDL) fraction are well-established risk factors
for the development of atherosclerosis. Atherosclerosis is a
systemic disease, commonly aﬀecting multiple vascular beds
[1] and is the leading cause of death in Europe [2]. Uptake
of native LDL into cells was ﬁrst proposed to be a crucial
initial step in the pathogenesis of atherosclerosis with the
discovery of the LDL receptor in the 1970’s by Goldstein and
Brown [3]. Their studies led to the elucidation of a pathway
by which the LDL-receptor complex undergoes receptor-
mediated endocytosis to enable it to be taken into the cell.
They observed that individuals with homozygous familial
hypercholesterolaemia (FH), who suﬀer with manifestations
of atherosclerosis in their teens, are completely lacking in
functional LDL receptors, and, therefore, their circulating
cholesterol levels are up to 5 times higher than in normal
individuals. However, this did not explain the observation
that patients with FH accumulated cholesterol in their cells
despite the lack of functional LDL receptors. Furthermore,
lipid-laden foam cells derived from patient tissues did not
develop in vitro even in the presence of high concentrations
of native LDL in contrast to controls. Their work led to
the now widely accepted view that the internalisation of a
modiﬁed form of LDL rather than native LDL is responsible
for the development of atherosclerotic plaque, and that this
occurs via membrane-bound receptors distinct to that of
the native LDL receptor. Basu et al. ﬁrst demonstrated this
in an experiment in which an iodine-labelled acetylated
form of LDL could induce massively increased cholesterol
accumulation in macrophages in vitro [4]. Further work
in vitro has shown that the oxidative modiﬁcation of LDL
increases the cellular content of cholesterol. Today, several
receptors have been identiﬁed that bind and internalise
oxidised LDL (OxLDL). This review focuses on one of those2 Cardiology Research and Practice
receptors, the lectin-like oxidised low-density lipoprotein
receptor-1(LOX-1)andexploresitspotentialasatherapeutic
target.
2. Modiﬁcation of LDL
The oxidative modiﬁcation of LDL results in a particle
with greatly increased proatherogenic and proinﬂammatory
properties than that of native LDL. It also becomes a ligand
for scavenger receptors but is not recognised by the native
LDL receptor, thought to be due to the greater net negative
charge [5]. The “average” LDL particle has been calculated
to contain 600 molecules of free cholesterol, 1600 molecules
of cholesteryl ester, 700 molecules of phospholipid, 180
molecules of triglyceride, and 1 molecule of apolipoprotein
B-100 [6]. All of these molecules can undergo oxidative
damage, and, therefore, understandably there is a spectrum
of oxidation level to the OxLDL created experimentally.
It is believed that the amount of OxLDL in the human
circulation is negligible, due to the presence of antioxidants.
OxLDL has, however, been extracted from human and rabbit
atherosclerotic plaque, in a form recognisable by scavenger
receptors [7]. The oxidation is likely to take place in pockets
within the subendothelial layer, where the cells produce both
free radical and nonradical oxidants, and the relative con-
centration of antioxidants is lower. The resulting OxLDL has
an immediate proatherogenic eﬀect; it causes the migration
of monocytes to the area via stimulation of the release of
monocyte chemoattractant protein-1 [8] and promotes the
diﬀerentiation of monocytes to macrophages by stimulating
the release of macrophage-colony stimulating factor from
endothelial cells [9]. OxLDL is cytotoxic to endothelial cells
in vitro and inhibits the vasodilation normally induced by
nitric oxide [10].
3. LOX-1
Modiﬁed LDL is internalized or endocytosed by membrane-
bound scavenger receptors, and as it stands today, numerous
scavenger receptors have been identiﬁed that recognize
OxLDL. Scavenger receptors are membrane-bound proteins
that are capable of binding a wide variety of ligands. The
scavengerreceptorfamilyissubdividedinto8subclasses.The
class A scavenger receptors all bind modiﬁed LDL and are
primarily expressed on macrophages. Class B includes the
CD36receptor,whichhasbeenshowntobindandinternalize
modiﬁed LDL [11]. The aﬃnity of the other classes to bind
modiﬁed LDL is less well described, except for the class E
receptor, lectin-like OxLDL receptor-1 (LOX-1).
LOX-1 (Genbank designation OLR1) was ﬁrst cloned
as a major receptor for OxLDL in 1997 by Sawamura and
colleagues [12] .L O X - 1i se x p r e s s e do nav a r i e t yo fc e l l
types, including endothelial cells, platelets, macrophages,
and smooth muscle cells [13–15]. The human ortholog is
a 50kDa type II transmembrane glycoprotein comprising
273 amino acids [12] .T h em a m m a l i a np r o t e i ni sc o m p r i s e d
of a short N-terminus cytoplasmic domain, transmembrane
domain, neck domain, and a C-type lectin-like domain
(CTLD). To function, LOX-1 requires oligomerisation of a
homodimer; this basal complex contains 2 LOX-1 polypep-
tides linked via an intermolecular disulﬁde bond in the neck
domainviaresidueC140[16].Evidenceincreasinglysuggests
that LOX-1 activity promotes vascular dysfunction and
atherosclerosis. LOX-1 ablation in transgenic murine models
reduces atherosclerotic plaque development [17]w h e r e a s
overexpression of LOX-1 in apolipoprotein E-null mice
increases atheroma-like lesions 10-fold [18]. Interestingly,
raised serum levels of a soluble LOX-1-derived proteolytic
fragment correlate with elevated acute coronary syndromes
(ACS) [19] and type II diabetes [20]. To date, seven single
nucleotide polymorphisms (SNP) within the LOX-1 gene
have been found (six noncoding, one coding) [21]. One
SNP appears to confer protection against OxLDL-induced
macrophage apoptosis [22], whereas the K167N polymor-
phism, resulting in a lysine to asparagine substitution,
increases the risk of myocardial infarction in a speciﬁc
patient cohort [23]. Numerous signal transduction pathways
are associated with LOX-1 activation by OxLDL binding
including RhoA/Rac1, p38MAPK, protein kinase B and
C, and ERK1/2, and blocking LOX-1 function in primary
endothelial cells inhibits proinﬂammatory signalling, NF-κB
activation, and apoptosis [24, 25].
3.1. Plasma Membrane Endocytosis of LOX-1. OxLDL is
rapidly internalised into cells upon binding LOX-1 and can
be observed in punctate perinuclear structures less than an
hour after exposure to a LOX-1 expressing cell (Figure 1).
This internalisation is blocked by the LOX-1-blocking-
antibody JTX92 [27], which prevents binding of OxLDL.
LOX-1 mediates early steps in internalisation of OxLDL
but within an hour of internalisation is mostly uncoupled
from OxLDL, and both molecules are located in separate
subcellular compartments within the cytosol [26]. This
internalisation pathway is not dependant on LOX-1 binding
to OxLDL as the receptor is constitutively endocytosed from
the plasma membrane.
The main form of receptor-mediated endocytosis is
clathrin-mediated endocytosis, but it has become apparent
that clathrin-independent pathways may represent up to
50% of cellular uptake [28]. Reverse genetic experiments
have shown that both the clathrin heavy chain and the AP-2
adaptor complex are not required for endocytosis of LOX-
1[ 26]. LOX-1 was also shown not to colocalise with the
caveolae marker caveolin-1. However, there is evidence that
caveolae may play a part in the endocytosis of OxLDL in
an endothelial model [29]. The dynamin-2 GTPase has been
shown to be essential for LOX-1 endocytosis as expression
of a dominant-negative protein defective in GTPase activity
blocked OxLDL uptake via the LOX-1 scavenger receptor
(Figure 2). The full mechanism by which LOX-1 endocytosis
occurs has yet to be established.
In eukaryote cells, receptor-mediated endocytosis is
regulatedbytherecognitionofcytoplasmicmotifsbycellular
machinery which promotes the selection of “cargo” for
transportwithintransportintermediatessuchasmembrane-
bound vesicles [30]. The cytoplasmic domain of LOX-1 doesCardiology Research and Practice 3
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Figure 1: Internalisation of OxLDL. Epithelial HeLa cells transiently expressing a LOX-1-FLAG protein (green) were incubated with
10μg/mL DiI-OxLDL (red) for 5mins at 37◦C (pulse) to allow binding (a), and chased for a further 55mins to allow internalization






Figure 2: Dynamin-2 regulates OxLDL endocytosis. Epithelial HeLa cells expressing both LOX-1-FLAG and either (a) wild-type dynamin 2
(green) or (b) a dynamin-2 K44A mutant (green) were incubated and chased with labelled Dil-OxLDL (red). Cells were ﬁxed and processed
forﬂuorescencemicroscopyusingpreviouslydescribedprocedures[26].ThenucleiwerestainedwithDAPI(blue).Bar,5μm.Aslicethrough
the cell is shown in the top half of the panel and a cross-section through the cell is shown at the bottom.
not contain any previously characterised motifs such as the
tyrosine-based motif YxxΦ or the di-leucine-based motifs.
Alanine-scanning mutagenesis of the LOX-1 cytoplasmic
domain allowed the identiﬁcation of a sequence of three
contiguous residues (DDL) at position +4 to +6 which
regulate LOX-1 endocytosis [31]. This diacidic DDL motif
thus deﬁnes a new class of novel endocytic motifs that
mediate clathrin- and AP2-independent endocytosis at the
plasma membrane. This motif is transplantable, as replace-
ment of the transferrin receptors cytoplasmic domain with
the LOX-1 cytoplasmic domain still promotes constitutive
endocytosis. Endocytosis of this transferrin receptor-LOX-
1 protein chimera was blocked by replacement of the DDL
motif with a triple alanine sequence, thus showing speciﬁcity
in this endocytosis [31].
Afterinternalizationattheplasmamembrane,LOX-1has
been shown to be separated from OxLDL in endosomes [27].
Immunoﬂuorescence studies demonstrate that after 15min
of internalization LOX-1 and OxLDL are colocalised in the

















Figure 3: Schematic diagram showing potential routes towards blocking OxLDL and/or LOX-1 function and traﬃcking to attenuate the
pathological process of atherosclerosis.
ligand binding, this codistribution disappears, indicating
that LOX-1 and OxLDL have now been sorted into sepa-
rate compartments. OxLDL is traﬃcked through the early
endosome and on to the lysosome for degradation. It is
believed that the majority of LOX-1 is targeted back to the
plasma membrane by a recycling pathway from endosome-
to-plasma membrane. Cytosolic factors that mediate recog-
nition, endocytosis, and/or recycling of LOX-1 have yet
to be identiﬁed. Targeting such factors using genetic or
pharmacological approaches would be a potential means of
blockingtheproatherogenicfunctionofLOX-1inpromoting
atherosclerosis.
LOX-1 appears to be essential for the phagocytosis of
aged and apoptotic cells in endothelial cells [32]. LOX-1
was demonstrated to be necessary for phagocytosis of such
cellular bodies in transfected Chinese hamster ovary cells,
but this is blocked by OxLDL indicating a competition
between OxLDL and apoptotic/aged bodies for binding to
the same or adjacent site on LOX-1. Phosphatidylserine (PS)
recognition on the plasma membrane of aged/apoptotic cells
has been shown to be important in their phagocytosis [33],
and LOX-1 is able to recognise PS on apoptotic cells in a
calcium-dependent manner [34].
LOX-1 endocytosis is also potentially important in
immune surveillance as it has been shown to regulate
antigen presentation by MHC class I and II molecules
on dendritic cells [35] and B cells [36]. LOX-1 is also
essential for the endocytosis of various heat shock proteins
(hsp’s) complexed to antigen-derived peptides [37]. LOX-1
is postulated to deliver the antigenic complex to endosome-
likecompartments,whereitispresumablyloadedontoMHC
molecules, which mediate antigen presentation to CD4+ and
CD8+ T cells.
4. Conclusion
Scavenger receptors are heavily implicated in the process of
atherosclerotic plaque formation [38]. This review focuses
on LOX-1; however, there is similar evidence for the
involvementofseveralotherclassesofscavengerreceptor.For
example, ApoE-null (−/−) mice lacking macrophage CD36
had an 88% decrease in atherosclerotic lesion area in the
aorta compared to controls [39], despite the heterogeneity
amongst the scavenger receptor family and their multiligand
capabilities, their targeting could prove fruitful in the
moderation of vascular disease, especially considering the
limitedsuccessofcurrenttreatmentmodalities.However,the
mosteﬀectivemeansoftargetinganddisrupting theOxLDL-
LOX-1 endocytic process remains unclear (Figure 3). The
OxLDL ligand itself could be targeted; in a murine model,
LOX-1 expressed ectopically in the liver via adenovirus
administration reduced levels of circulating OxLDL and
inhibited the formation of atherosclerotic lesions [40], gene
therapy with possible genomic manipulation of scavenger
receptor expression by delivery of transgenes or by blockade
ofgeneexpressionmaybepossible[41].Furtherunderstand-
ing of the proteins that facilitate OxLDL transfer across the
endothelium may allow the development of pharmaceutical
agents that inhibit its endocytosis. Finally, the role of the
soluble fragment of the LOX-1 receptor that is shed into the
circulation is unclear, but the study of its use as a biomarker
in the treatment of cardiovascular disease is promising.
Signiﬁcant recent progress has been made in the elucida-
tion of the pathways of internalization of the OxLDL-LOX-1
complex; however, there remains much to be done to further
characterise the role of this multiligand scavenger receptor
in regulating human health and disease. The existence ofCardiology Research and Practice 5
several diﬀerent subclasses of scavenger receptor capable
of internalising OxLDL makes the development of targeted
therapies a more complex issue. The molecular study of
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